TCTMD4h
Little Pre- and Postmarket Testing for Most Recalled CV Devices
The majority of FDA-recalled devices made it to market via the 510(k) pathway, which doesn’t require new clinical or safety ...
TCTMD4h
Access to Cardiac PET Limited in Many Parts of the US
Growing interest in the technology plus a novel tracer on the way may induce change in coming years, says Marcelo Di Carli.
TCTMD5h
Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home
The AT HOME-HF pilot study suggests this approach to diuretic delivery can safely improve symptoms and function.